

**Louisiana Department of Health
Medicaid Pharmaceutical and Therapeutics Committee
628 North Fourth Street
Baton Rouge, LA
Bienville Building, Room #118
May 5, 2023
9:00 AM
*Draft***

- I. Call to Order.....Ben Orlando
- II. Parliamentary Business Ben Orlando
 - A. Introduction of Members/Roll Call
 - B. Attendance/Additional Meetings
 - C. Approval of November 4, 2022 Meeting Minutes
- III. P & T Committee Review Virtual Process.....Hind Douiki
- IV. Reports.....Melwyn Wendt
 - A. PDL Reflecting Fall 2022 Recommendations
- V. New Business.....Hind Douiki
 - A. Explanation of TOP\$, Monographs and Cost Sheets
 - B. Therapeutic Class Reviews of Drug Classes/Drug Manufacturer Testimony
 - 1. Acne Agents, Topical
 - 2. Analgesics, Narcotics Long
 - 3. Analgesics, Narcotics Short
 - 4. Androgenic Agents
 - 5. Angiotensin Modulator Combinations
 - 6. Angiotensin Modulators
 - 7. Antibiotics, GI
 - 8. Antibiotics, Inhaled
 - 9. Antibiotics, Topical
 - 10. Antibiotics, Vaginal
 - 11. Anticoagulants
 - 12. Antiemetic/Antivertigo Agents
 - 13. Antifungals, Oral
 - 14. Antifungals, Topical
 - 15. Antimigraine Agents, Other
 - 16. Antimigraine Agents, Triptans
 - 17. Antiparasitics, Topical
 - 18. Antivirals, Oral
 - 19. Antivirals, Topical
 - 20. Beta-Blockers
 - 21. Bladder Relaxant Preparations
 - 22. Bone Resorption Suppression and Related Agents
 - 23. BPH Treatments

24. Calcium Channel Blockers
25. Cephalosporins and Related Antibiotics
26. Cystic Fibrosis, Oral
27. Fluoroquinolones, Oral
28. GI Motility, Chronic
29. Glucagon Agents
30. Growth Factors
31. Growth Hormone
32. H. Pylori Treatment
33. HAE Treatments
34. HIV/AIDS
35. Hypoglycemics, Alpha-Glucosidase Inhibitors
36. Hypoglycemics, Incretin Mimetics/Enhancers
37. Hypoglycemics, Insulin and Related Agents
38. Hypoglycemics, Meglitinides
39. Hypoglycemics, Metformins
40. Hypoglycemics, SGLT2
41. Hypoglycemics, Sulfonylureas
42. Hypoglycemics, TZD
43. Immunosuppressives, Oral
44. Lincosamides/Oxazolidinones/Streptogramins
45. Lipotropics, Other
46. Lipotropics, Statins
47. Macrolides/Ketolides
48. Multiple Sclerosis Agents
49. Nitrofurans Derivatives
50. Opiate Dependence Treatments
51. PAH Agents, Oral and Inhaled
52. Pancreatic Enzymes
53. Pediatric Vitamin Preparations
54. Phosphate Binders
55. Pituitary Suppressive Agents, LHRH
56. Platelet Aggregation Inhibitors
57. Pleuromutilins
58. Potassium Binders
59. Proton Pump Inhibitors
60. Sinus Node Inhibitors
61. Skeletal Muscle Relaxants
62. Tetracyclines
63. Ulcerative Colitis Agents
64. Uterine Disorder Treatments
65. Vasodilators, Coronary

C. Hepatitis C Agents

66. Antidepressants, SSRIs – Auvelity® (Oral)
67. Colony Stimulating Factors – Fylnetra® (Subcutaneous)
68. Colony Stimulating Factors - Stimufend® Syringe (Subcutaneous)
69. Colony Stimulating Factors - Rolvedon® Syringe (Subcutaneous)
70. Cytokine and CAM Antagonists - Amjevita Autoinjector LC (Subcutaneous)
71. Cytokine and CAM Antagonists - Amjevita Syringe (Subcutaneous)
72. Cytokine and CAM Antagonists - Amjevita Autoinjector HC (Subcutaneous)Cytokine and CAM Antagonists - Sotyktu® (Oral)
73. Cytokine and CAM Antagonists – Spevigo® (Intraven.)
74. Hemophilia Treatment – Hemgenix® (Intraven.)
75. Oncology, Oral – Hematologic - Rezlidhia® (Oral)
76. Oncology, Oral – Other - Lytgobi® (Oral)
77. Stimulants and Related Agents – Xelstrym® (Transdermal)

VII. Other Changes

78. Antipsychotics— Latuda® (Oral)
79. Antipsychotics— Lurasidone(Oral)

VIII. Other Business

IX. Next Steps

- A. Proposed Therapeutic Classes to be Reviewed at Next Meeting

X. Next Meeting Date – Friday, October 25, 2023

XI. Public Testimony